AIM: Glucagon is a key regulator of glucose and energy metabolism, yet the dose-response effects of glucagon on markers of metabolism in humans are not fully characterised. We investigated the dose-dependent effects of glucagon on glucose metabolism, β-cell secretion and markers of hepatic metabolism in healthy adults. MATERIALS AND METHODS: ). Plasma glucose, insulin, C-peptide, cyclic AMP (cAMP), non-esterified fatty acids, triglycerides, total amino acids and urea were measured repeatedly throughout the study. RESULTS: Plasma glucose increased in a dose-dependent manner, with significant stepwise elevations observed from intermediate infusion rates and reaching peak levels at supraphysiological glucagon levels. Insulin and C-peptide levels rose markedly, reflecting β-cell activation. Plasma cAMP increased only during the highest glucagon infusion rate, despite earlier metabolic responses. Plasma non-esterified fatty acids, triglycerides and total amino acids declined at higher glucagon doses, whilst plasma urea decreased gradually from the second infusion rate onward. CONCLUSION: Infusion of glucagon results in dose-dependent metabolic effects in healthy humans. The differential timing of glucose, lipid and amino acid responses relative to systemic cAMP elevations could be consistent with pathway-specific activation thresholds rather than uniform signalling. These findings provide new insights into human glucagon physiology with potential relevance for metabolic diseases.
Brock et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: